Ladenburg Thalmann

A combination of a large total addressable market, regulatory clearance, strong partnerships and effective product has Ladenburg Thalmann analysts bullish on electroCore, Inc. (NASDAQ: ECOR). The electroCore Analyst: Jeffrey Cohen initiated coverage on electroCore with a Buy rating and $3...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. This year has gotten off to a strong start already. Many stocks, including penny stocks, are reaching new 52-week and all-time highs....

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...

Sage Therapeutics Inc (NASDAQ: SAGE) is a buy ahead of the commercial launch of its safer alternatives to existing antidepressants, according to Ladenburg Thalmann. The Analyst Ladenburg Thalmann's Michael Higgins initiated coverage of Sage Therapeutics' stock with a Buy rating and $...

Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...

Following the presentation of encouraging pre-clinical data from Novavax, Inc. (NASDAQ: NVAX)'s nanoparticle influenza vaccine, Ladenburg Thalmann upgraded shares of the company. The rating on the stock now goes from Neutral to Buy, with a $1.60 price target. The shares of Novavax were trading up 1...

If you've been too distracted by the Snap Inc (NYSE: SNAP) IPO lottery ticket trade to keep your eye on small-cap biotech moves, you may not have noticed VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV) shares quietly doubling in value since the start of the year. VBI Vaccines is a...

Vievu filed a complaint against TASER International, Inc. (NASDAQ: TASR) in February alleging illegal conduct and tortious interference during a bid war for body camera contracts in Phoenix, Arizona. The plaintiff, who ultimately lost the contract, said Taser illegally lobbied the client and...

TASER International, Inc. (NASDAQ: TASR) reported strong revenue results, but delivered a weak margin performance due to high opex [operating expenses]. Although TASER’s video business is “rapidly achieving scale,” there are concerns around intensifying competition, Ladenburg...

“While we continue to believe Novavax, Inc. (NASDAQ: NVAX) has an active vaccine for the prevention of RSV (Respiratory syncytial virus), we view a Neutral rating as appropriate given limited visibility on optimal dose/schedule for future development in an elderly population and modest...

Biotechnology stocks have experienced high price and volume fluctuations that “have often been unrelated or disproportionate to the operating performance of companies, ” according to Ladenburg Thalmann analysts. Against this backdrop, Ladenburg Thalmann initiated coverage of two biotech...

Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis has largely played out. Q2 Largely In Line Analyst Kevin DeGeeter noted that the company reported second-quarter non-GAAP earnings of $0.26 per share on revenues...

Despite a January 18 patient death during Stemline Therapeutics Inc (NASDAQ: STML)’s ongoing SL-401 trials, Ladenburg Thalmann reiterated a Buy rating on the company, the blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment study of which is continuing to enroll new participants....

Ladenburg Thalmann’s Christopher S. James initiated coverage of four biotech companies with a Buy rating, given that each has a promising lead drug candidate that is expected to drive growth in the near future. Achillion Pharmaceuticals James initiated coverage of Achillion Pharmaceuticals,...

Ladenburg Thalmann has downgraded Cempra Inc (NASDAQ: CEMP) to Neutral from Buy following the complete response letter from the FDA for Solithromycin for treatment of Community Acquired Bacterial Pneumonia (CABP). The letter cites both manufacturing deficiencies at contract manufacturer Wockhardt...